ライフサイエンスコーパス: erythropoiesis-stimulating agent

1 increased morbidity and mortality related to erythropoiesis stimulating agents.

2 overanticoagulation, and adverse effects of erythropoiesis-stimulating agents.

3 OR downmodulation and trafficking, and novel erythropoiesis-stimulating agents.

4 o 4.7 g/dL) in the absence of transfusion or erythropoiesis-stimulating agents.

5 sions (42 [10%] vs seven [3%]; p=0.003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%];

6 Erythropoiesis stimulating agent administration in sTBI

7 Erythropoiesis-stimulating agent administration to patie

8 In view of the expense of erythropoiesis stimulating agents and the uncertainty of

9 Erythropoiesis-stimulating agents and blood transfusion

10 variability are because of the therapy with erythropoiesis-stimulating agents and/or iron or despite

11 should be reevaluated to include infection, erythropoiesis-stimulating agents, and blood transfusion

12 -and-see approach for asymptomatic patients, erythropoiesis-stimulating agents, androgens, or immunom

13 gradually moved away from the liberal use of erythropoiesis-stimulating agents as the main treatment

14 Addition of an erythropoiesis-stimulating agent could improve response

15 Erythropoiesis-stimulating agents do not seem to benefit

16 Erythropoiesis stimulating agent (ESA) administration ma

17 beling was applied for the first time to the erythropoiesis stimulating agent (ESA) products, which f

18 ), serum bicarbonate, and creatinine; use of erythropoiesis-stimulating agent (ESA) and iron; and imm

19 trials showed worse clinical outcomes in the erythropoiesis-stimulating agent (ESA) arm.

20 mmittee continues to recommend initiating an erythropoiesis-stimulating agent (ESA) as hemoglobin (Hb

21 Peginesatide is a peptide-based erythropoiesis-stimulating agent (ESA) that may have the

22 Peginesatide, a synthetic peptide-based erythropoiesis-stimulating agent (ESA), is a potential t

23 Poor response to erythropoiesis-stimulating agents (ESA) is associated wi

24 treating anemia of chronic kidney disease by erythropoiesis-stimulating agents (ESA) may improve surv

25 Recombinant erythropoietin (EPO) analogs [erythropoiesis-stimulating agents (ESA)] are clinically

26 evel variability, especially with the use of erythropoiesis stimulating agents (ESAs) and iron.

27 Erythropoiesis stimulating agents (ESAs) have been repor

28 erythropoiesis and blunting the activity of erythropoiesis stimulating agents (ESAs).

29 nt practice by estimating its typical use of erythropoiesis-stimulating agents (ESAs) and intravenous

30 Erythropoiesis-stimulating agents (ESAs) are commonly us

31 n supplementation alone and as an adjunct to erythropoiesis-stimulating agents (ESAs) compared with E

32 Non-placebo-controlled trials of erythropoiesis-stimulating agents (ESAs) comparing lower

33 African Americans require higher doses of erythropoiesis-stimulating agents (ESAs) during dialysis

34 The erythropoiesis-stimulating agents (ESAs) erythropoietin

35 m (PPS) and changes to dosing guidelines for erythropoiesis-stimulating agents (ESAs) in 2011 appear

36 ed controlled trials assessing the effect of erythropoiesis-stimulating agents (ESAs) in critically i

37 ional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete

38 Clinical Oncology recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients wit

39 l-based approaches to anemia management with erythropoiesis-stimulating agents (ESAs) may result in u

40 The use of erythropoiesis-stimulating agents (ESAs) such as erythro

41 Erythropoiesis-stimulating agents (ESAs) were prescribed

42 ony-stimulating factor support was required; erythropoiesis-stimulating agents (ESAs) were used at th

43 odysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a respons

44 stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs).

45 analysis to determine the patterns of use of erythropoiesis-stimulating agents (ESAs).

46 ir management with RBV dose reduction and/or erythropoiesis-stimulating agents (ESAs).

47 ism and concern of potential harm from using erythropoiesis-stimulating agents (ESAs).

48 Among patients who were not receiving erythropoiesis-stimulating agents, hemoglobin increased

49 Among patients who were receiving erythropoiesis-stimulating agents, hemoglobin increased

50 implementation of restrictions on the use of erythropoiesis-stimulating agents in cancer may impact b

51 Immunosuppressants, erythropoiesis-stimulating agents in combination with gr

52 NDATION 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild

53 s indicating a possible beneficial effect of erythropoiesis-stimulating agents in the treatment of an

54 thus, this study does not support the use of erythropoiesis-stimulating agents in this subset of pati

55 survival pathways, the development of novel erythropoiesis-stimulating agents, increasing evidence f

56 This long-acting erythropoiesis-stimulating agent is as safe as conventio

57 in less than 100 g/L (10 g/dL) and/or use of erythropoiesis-stimulating agents, leukocyte count more

58 Both pharmacologic features and dosing of erythropoiesis-stimulating agents may lead to cyclic pat

59 ansfusions for reasons such as resistance to erythropoiesis-stimulating agents or cardiovascular inst

60 nofsky performance status (KPS), exposure to erythropoiesis-stimulating agents, presence of central v

61 Erythropoiesis stimulating agents remain the first-line

62 Trials raising concerns about erythropoiesis-stimulating agents, revisions to their la

63 sed resistance to supraphysiologic levels of erythropoiesis-stimulating agent, supporting the hypothe

64 to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offe

65 Despite the near universal use of erythropoiesis-stimulating agents, there are still occas

66 d from myelodysplastic syndromes, relying on erythropoiesis-stimulating agents to cope with anemia, a

67 And for emerging erythropoiesis-stimulating agents, to what extent do act

68 ems have provided strong stimuli to decrease erythropoiesis-stimulating agent use and increase intrav

69 Treatment with lenalidomide and erythropoiesis-stimulating agents was shown to be an ind

70 e reversed, treatment options are limited to erythropoiesis-stimulating agents with or without intrav

71 Treatment studies have focused on the use of erythropoiesis-stimulating agents, with recent trials sh